Evidence map›Paper›PMID 29773556›Full record

ArticleGenes & development2018

PRDX1 and MTH1 cooperate to prevent ROS-mediated inhibition of telomerase.

Wareed Ahmed, Joachim Lingner

Open access · diamondAbstract read
In one paragraph

Article in Genes & development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 75 citations in OpenAlex.

  1. PBMC telomerase activity in depression and the response to electroconvulsive therapy.European archives of psychiatry and clinical neuroscience · 2021
    Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Oxidative Stress and DNA Damage at Telomeres.Cold Spring Harbor perspectives in biology · 2025
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Telomere Reprogramming and Cellular Metabolism: Is There a Link?International journal of molecular sciences · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Wareed AhmedSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.
Joachim LingnerSwiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne (EPFL), 1015 Lausanne, Switzerland.ORCID 0000-0002-2853-5803
École Polytechnique Fédérale de Lausanne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Telomerase counteracts telomere shortening and cellular senescence in germ, stem, and cancer cells by adding repetitive DNA sequences to the ends of chromosomes. Telomeres are susceptible to damage by reactive oxygen species (ROS), but the consequences of oxidation of telomeres on telomere length and the mechanisms that protect from ROS-mediated telomere damage are not well understood. In particular, 8-oxoguanine nucleotides at 3' ends of telomeric substrates inhibit telomerase in vitro, whereas, at internal positions, they suppress G-quadruplex formation and were therefore proposed to promote telomerase activity. Here, we disrupt the peroxiredoxin 1 (

Indexed as

DNA DamageDNA Repair EnzymesEnzyme ActivationGene Knockout TechniquesGenomeGuanineHCT116 CellsHumansOxidation-ReductionOxidative StressPeroxiredoxinsPhosphoric Monoester HydrolasesReactive Oxygen SpeciesTelomeraseTelomere HomeostasisTelomere Shortening8-oxodGTPaseDNA Repair EnzymesGuaninePeroxiredoxinsPhosphoric Monoester HydrolasesPRDX1 protein, humanReactive Oxygen SpeciesTelomeraseagingcellular senescenceMTH1oxidative stressPRDX1telomerasetelomeres

Identifiers

PMID29773556
PMCPMC6004070
OpenAlexW2803653803

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.